Antecedent  ||| S:0 E:11 ||| JJ
cardiovascular  ||| S:11 E:26 ||| JJ
disease  ||| S:26 E:34 ||| NN
and  ||| S:34 E:38 ||| CC
autoimmunity  ||| S:38 E:51 ||| NN
in  ||| S:51 E:54 ||| IN
Philadelphia-negative  ||| S:54 E:76 ||| JJ
chronic  ||| S:76 E:84 ||| JJ
myeloproliferative  ||| S:84 E:103 ||| NNS
neoplasms  ||| S:103 E:113 ||| VBP
A  ||| S:113 E:115 ||| DT
single  ||| S:115 E:122 ||| JJ
institution  ||| S:122 E:134 ||| NN
case-control  ||| S:134 E:147 ||| JJ
study  ||| S:147 E:153 ||| NN
was  ||| S:153 E:157 ||| VBD
conducted  ||| S:157 E:167 ||| VBN
to  ||| S:167 E:170 ||| TO
evaluate  ||| S:170 E:179 ||| VB
the  ||| S:179 E:183 ||| DT
risk  ||| S:183 E:188 ||| NN
of  ||| S:188 E:191 ||| IN
developing  ||| S:191 E:202 ||| VBG
chronic  ||| S:202 E:210 ||| JJ
myeloproliferative  ||| S:210 E:229 ||| JJ
neoplasms  ||| S:229 E:239 ||| NNS
( ||| S:239 E:240 ||| -LRB-
MPNs ||| S:240 E:244 ||| NNP
)  ||| S:244 E:246 ||| -RRB-
associated  ||| S:246 E:257 ||| VBN
with  ||| S:257 E:262 ||| IN
prior  ||| S:262 E:268 ||| JJ
autoimmune  ||| S:268 E:279 ||| JJ
disease  ||| S:279 E:287 ||| NN
and  ||| S:287 E:291 ||| CC
cardiovascular  ||| S:291 E:306 ||| JJ
disease  ||| S:306 E:314 ||| NN
( ||| S:314 E:315 ||| -LRB-
CVD ||| S:315 E:318 ||| NNP
) ||| S:318 E:319 ||| -RRB-
.  ||| S:319 E:321 ||| .
Cases  ||| S:321 E:327 ||| NNS
were  ||| S:327 E:332 ||| VBD
323  ||| S:332 E:336 ||| CD
MPN  ||| S:336 E:340 ||| NN
patients  ||| S:340 E:349 ||| NNS
and  ||| S:349 E:353 ||| CC
controls  ||| S:353 E:362 ||| NNS
were  ||| S:362 E:367 ||| VBD
333  ||| S:367 E:371 ||| CD
chronic  ||| S:371 E:379 ||| JJ
lymphocytic  ||| S:379 E:391 ||| JJ
leukemia  ||| S:391 E:400 ||| NN
( ||| S:400 E:401 ||| -LRB-
CLL ||| S:401 E:404 ||| NNP
)  ||| S:404 E:406 ||| -RRB-
patients ||| S:406 E:414 ||| NNS
.  ||| S:414 E:416 ||| .
Odds  ||| S:416 E:421 ||| NNS
ratios  ||| S:421 E:428 ||| NNS
( ||| S:428 E:429 ||| -LRB-
ORs ||| S:429 E:432 ||| NNP
)  ||| S:432 E:434 ||| -RRB-
and  ||| S:434 E:438 ||| CC
p-values  ||| S:438 E:447 ||| JJ
using  ||| S:447 E:453 ||| VBG
Fischer ||| S:453 E:460 ||| NNP
's  ||| S:460 E:463 ||| POS
exact  ||| S:463 E:469 ||| JJ
tests  ||| S:469 E:475 ||| NNS
were  ||| S:475 E:480 ||| VBD
calculated ||| S:480 E:490 ||| VBN
.  ||| S:490 E:492 ||| .
The  ||| S:492 E:496 ||| DT
data  ||| S:496 E:501 ||| NNS
was  ||| S:501 E:505 ||| VBD
adjusted  ||| S:505 E:514 ||| VBN
for  ||| S:514 E:518 ||| IN
confounding  ||| S:518 E:530 ||| JJ
effects  ||| S:530 E:538 ||| NNS
by  ||| S:538 E:541 ||| IN
logistic  ||| S:541 E:550 ||| JJ
regression ||| S:550 E:560 ||| NN
.  ||| S:560 E:562 ||| .
A  ||| S:562 E:564 ||| DT
significantly  ||| S:564 E:578 ||| RB
increased  ||| S:578 E:588 ||| VBN
risk  ||| S:588 E:593 ||| NN
of  ||| S:593 E:596 ||| IN
MPNs  ||| S:596 E:601 ||| JJ
compared  ||| S:601 E:610 ||| VBN
to  ||| S:610 E:613 ||| TO
CLL  ||| S:613 E:617 ||| NNP
was  ||| S:617 E:621 ||| VBD
observed  ||| S:621 E:630 ||| VBN
in  ||| S:630 E:633 ||| IN
subjects  ||| S:633 E:642 ||| NNS
with  ||| S:642 E:647 ||| IN
a  ||| S:647 E:649 ||| DT
prior  ||| S:649 E:655 ||| JJ
history  ||| S:655 E:663 ||| NN
of  ||| S:663 E:666 ||| IN
any  ||| S:666 E:670 ||| DT
autoimmune  ||| S:670 E:681 ||| JJ
disease  ||| S:681 E:689 ||| NN
( ||| S:689 E:690 ||| -LRB-
OR=1.86 ||| S:690 E:697 ||| NNP
,  ||| S:697 E:699 ||| ,
95 ||| S:699 E:701 ||| CD
% ||| S:701 E:702 ||| NN
CI  ||| S:702 E:705 ||| NNP
1.16-2.98 ||| S:705 E:714 ||| NNP
) ||| S:714 E:715 ||| -RRB-
.  ||| S:715 E:717 ||| .
A  ||| S:717 E:719 ||| DT
positive  ||| S:719 E:728 ||| JJ
association  ||| S:728 E:740 ||| NN
between  ||| S:740 E:748 ||| IN
JAK2-V617F  ||| S:748 E:759 ||| CD
positive  ||| S:759 E:768 ||| JJ
MPN  ||| S:768 E:772 ||| NNP
and  ||| S:772 E:776 ||| CC
any  ||| S:776 E:780 ||| DT
autoimmune  ||| S:780 E:791 ||| JJ
disease  ||| S:791 E:799 ||| NN
was  ||| S:799 E:803 ||| VBD
observed  ||| S:803 E:812 ||| VBN
at  ||| S:812 E:815 ||| IN
follow-up  ||| S:815 E:825 ||| NNP
( ||| S:825 E:826 ||| -LRB-
OR=2.62 ||| S:826 E:833 ||| NNP
,  ||| S:833 E:835 ||| ,
95 ||| S:835 E:837 ||| CD
%  ||| S:837 E:839 ||| NN
CI  ||| S:839 E:842 ||| NNP
1.21-5.67 ||| S:842 E:851 ||| NNP
) ||| S:851 E:852 ||| -RRB-
.  ||| S:852 E:854 ||| .
A  ||| S:854 E:856 ||| DT
significantly  ||| S:856 E:870 ||| RB
increased  ||| S:870 E:880 ||| VBN
risk  ||| S:880 E:885 ||| NN
of  ||| S:885 E:888 ||| IN
MPN  ||| S:888 E:892 ||| NNP
compared  ||| S:892 E:901 ||| VBN
to  ||| S:901 E:904 ||| TO
CLL  ||| S:904 E:908 ||| NNP
was  ||| S:908 E:912 ||| VBD
also  ||| S:912 E:917 ||| RB
observed  ||| S:917 E:926 ||| VBN
in  ||| S:926 E:929 ||| IN
subjects  ||| S:929 E:938 ||| NNS
with  ||| S:938 E:943 ||| IN
prior  ||| S:943 E:949 ||| JJ
thromboembolic  ||| S:949 E:964 ||| JJ
events  ||| S:964 E:971 ||| NNS
( ||| S:971 E:972 ||| -LRB-
TE-events ||| S:972 E:981 ||| NNP
)  ||| S:981 E:983 ||| -RRB-
( ||| S:983 E:984 ||| -LRB-
OR=2.09 ||| S:984 E:991 ||| NNP
,  ||| S:991 E:993 ||| ,
95 ||| S:993 E:995 ||| CD
% ||| S:995 E:996 ||| NN
CI  ||| S:996 E:999 ||| NNP
1.42-3.08 ||| S:999 E:1008 ||| NNP
) ||| S:1008 E:1009 ||| -RRB-
.  ||| S:1009 E:1011 ||| .
In  ||| S:1011 E:1014 ||| IN
the  ||| S:1014 E:1018 ||| DT
MPN  ||| S:1018 E:1022 ||| NNP
group ||| S:1022 E:1027 ||| NN
,  ||| S:1027 E:1029 ||| ,
an  ||| S:1029 E:1032 ||| DT
increased  ||| S:1032 E:1042 ||| JJ
risk  ||| S:1042 E:1047 ||| NN
of  ||| S:1047 E:1050 ||| IN
JAK2-V617F-positive  ||| S:1050 E:1070 ||| CD
disease  ||| S:1070 E:1078 ||| NN
was  ||| S:1078 E:1082 ||| VBD
observed  ||| S:1082 E:1091 ||| VBN
in  ||| S:1091 E:1094 ||| IN
subjects  ||| S:1094 E:1103 ||| NNS
with  ||| S:1103 E:1108 ||| IN
prior  ||| S:1108 E:1114 ||| JJ
TE-events  ||| S:1114 E:1124 ||| NN
( ||| S:1124 E:1125 ||| -LRB-
OR=2.19 ||| S:1125 E:1132 ||| NNP
,  ||| S:1132 E:1134 ||| ,
95 ||| S:1134 E:1136 ||| CD
% ||| S:1136 E:1137 ||| NN
CI  ||| S:1137 E:1140 ||| NNP
1.51-3.16 ||| S:1140 E:1149 ||| NNP
) ||| S:1149 E:1150 ||| -RRB-
.  ||| S:1150 E:1152 ||| .
It  ||| S:1152 E:1155 ||| PRP
is  ||| S:1155 E:1158 ||| VBZ
discussed  ||| S:1158 E:1168 ||| VBN
if  ||| S:1168 E:1171 ||| IN
chronic  ||| S:1171 E:1179 ||| JJ
inflammation  ||| S:1179 E:1192 ||| NN
in  ||| S:1192 E:1195 ||| IN
relation  ||| S:1195 E:1204 ||| NN
to  ||| S:1204 E:1207 ||| TO
autoimmunity  ||| S:1207 E:1220 ||| VB
and  ||| S:1220 E:1224 ||| CC
atherosclerosis  ||| S:1224 E:1240 ||| NNS
might  ||| S:1240 E:1246 ||| MD
elicit  ||| S:1246 E:1253 ||| VB
mutations  ||| S:1253 E:1263 ||| VBN
in  ||| S:1263 E:1266 ||| IN
the  ||| S:1266 E:1270 ||| DT
hematopoietic  ||| S:1270 E:1284 ||| JJ
stem  ||| S:1284 E:1289 ||| NN
cell  ||| S:1289 E:1294 ||| NN
resulting  ||| S:1294 E:1304 ||| VBG
in  ||| S:1304 E:1307 ||| IN
MPNs ||| S:1307 E:1311 ||| NNP
,  ||| S:1311 E:1313 ||| ,
or  ||| S:1313 E:1316 ||| CC
whether  ||| S:1316 E:1324 ||| IN
this  ||| S:1324 E:1329 ||| DT
association  ||| S:1329 E:1341 ||| NN
actually  ||| S:1341 E:1350 ||| RB
reflects  ||| S:1350 E:1359 ||| VBZ
a  ||| S:1359 E:1361 ||| DT
long-lasting  ||| S:1361 E:1374 ||| JJ
pre-MPN-diagnosis  ||| S:1374 E:1392 ||| JJ
phase ||| S:1392 E:1397 ||| NN
,  ||| S:1397 E:1399 ||| ,
in  ||| S:1399 E:1402 ||| IN
which  ||| S:1402 E:1408 ||| WDT
the  ||| S:1408 E:1412 ||| DT
MPN-disease  ||| S:1412 E:1424 ||| JJ
per  ||| S:1424 E:1428 ||| FW
se  ||| S:1428 E:1431 ||| FW
contributes  ||| S:1431 E:1443 ||| FW
to  ||| S:1443 E:1446 ||| TO
a  ||| S:1446 E:1448 ||| DT
chronic  ||| S:1448 E:1456 ||| JJ
inflammatory  ||| S:1456 E:1469 ||| JJ
state  ||| S:1469 E:1475 ||| NN
and  ||| S:1475 E:1479 ||| CC
immune  ||| S:1479 E:1486 ||| JJ
deregulation ||| S:1486 E:1498 ||| NN
.  ||| S:1498 E:1500 ||| .
